Deliver Your News to the World

Merck Receives Not Approvable Letter from FDA for OTC MEVACOR® (lovastatin) 20 mg


WHITEHOUSE STATION, N.J.- Merck & Co., Inc. received a not approvable letter from the U.S Food and Drug Administration (FDA) to its New Drug Application (NDA) seeking approval for over-the-counter (OTC) MEVACOR® (lovastatin) 20 mg. MEVACOR OTC had been under review by the FDA since 1999; Advisory Committee reviews in 2000 and 2005 resulted in not approvable actions.

The FDA indicated in its letter that it would require a revised label and additional data from Merck in order to gain marketing approval. “We’re evaluating the conditions outlined in the agency’s response to determine a path forward for MEVACOR OTC,” said Edwin L. Hemwall, PhD, vice president, Global OTC Regulatory and Scientific Affairs.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.